Global Intravenous (IV) Iron Drugs Market: 2011 Edition

Iron is one of the most important minerals present in the human body and performs the task of carrying oxygen throughout the body through blood, which is then further utilized by the cells to get energy. Decline in iron can therefore lead to certain major problems. Although oral iron supplements can be used to maintain the iron levels in the body, but oral supplements are chronic treatments and generally have poor absorption, poor compliance, and can have certain side effects. In such cases, IV iron therapy proves out to be the best option. Presently, oral iron dominates the global iron market, holding more than half of the market. But with the increasing use of IV iron, its share is expected to increase and surpass that of oral iron.

The global market for IV iron is increasing in the past years. Nephrology remains the largest segment of use for the IV iron therapies, and accounts for more than three-fourths of the overall market. With the ongoing research and development to increase the use of IV iron therapies in other therapeutic areas, including gynaecology, gastroenterology, oncology, chronic heart failures and surgeries, the IV iron market would certainly benefit. There are certain types of IV iron products being marketed and used worldwide, some of which include low molecular weight iron dextran, iron sucrose, ferric gluconate, and ferric carboxylmaltose. The US is the largest IV iron market worldwide, followed by European Union.

More than 90% of the dialysis patients receive IV iron therapies, and there is an expected increase in the number of dialysis patients, on the back of ageing population, growing prevalence of hypertension, obesity and diabetes. Therefore, the global IV iron market is likely to increase in the coming years.

Vifor Pharma, a part of Galenica Group is the leading company in IV Iron market worldwide, with its two products, Venofre and Ferinject. Some of the other major companies in this sector include Watson Pharmaceuticals (INFeD), and AMAG Pharmaceuticals (Feraheme).

The present report analyzes the global IV iron market, with focus on some of the major regional markets, including the US, Europe and Switzerland. Major drivers being discussed in this report are rapidly ageing population, increase use of IV iron in gynecology, and improving results of IV iron in other therapeutic areas including the chronic heart diseases and pre dialysis. Also, the report presents some of the major issues concerning the industry. The leading companies are being profiled, along with their key financials and strategies for growth.

By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests.
[Studien Infos ausblenden]

1. Intravenous (IV) Iron: An Introduction

1.1 Intravenous Treatment – Overview
1.2 Intravenous Iron Treatment

2. IV Iron Market

2.1 Global Market for Iron Products

Market Value
Market Segments

2.2 Global IV Iron Market

Market Value
Market Segments

3. Major IV Iron Regional Markets

3.1 The US IV Iron Market

3.1.1 Overview

Market Volume
Volume Share

3.1.2 Potential in the Non-Dialysis Dependant CKD IDA Market

3.2 European Union Iron Market

3.2.1 Introduction
3.2.2 IV Iron Market in Switzerland

Market Volume
Product Segments
Value Share

4. Growth Drivers

4.1 Increasing Opportunity in Nephrology
4.2 Growing Prevalence of Diabetes
4.3 Rapidly Ageing Population
4.4 Increasing Use of IV Iron in Gynaecology
4.5 IV Iron Improves Quality of Treatment outside Dialysis

5. Key Issues

5.1 Treatment Costs
5.2 Concerns Regarding Adverse Effects
5.3 Stringent Regulations

6. Company Profiles

6.1 Galenica Pharmaceuticals

Business Description
Key Financials
Business Strategies
Strategic Alliances
Commitment to R&D

6.2 Watson Pharmaceuticals

Business Description
Key Financials
Business Strategies
Significant Contribution to R&D
Expansion through Acquisitions

6.3 AMAG Pharmaceuticals

Business Description
Key Financials
Business Strategies
Focus on R&D
Continued Focus on Feraheme

7. Market Outlook

7.1 Market Forecast
7.2 Forecast Methodology
7.2.1 Dependent and Independent Variables
7.2.2 Correlation Analysis
7.2.3 Regression Analysis
?
List of Charts

Global Market for Iron Products (2006-2010)
Global Iron Products Market – Share by Segments (2010)
Global IV Iron Market (2006-2010)
IV Iron Market – Share by Area of Use (2010)
Global IV Iron Market – Share by Major Products (2006-2010)
US IV Iron Replacement Market – by Volume (2008-2010)
US IV Iron Replacement Market – Volume Share by Category of Use (2010)
US IV Iron Replacement Market – Volume Share by Products (2010)
US CKD Patient Profile
US Non-Dialysis IV Iron Market – by Quarter (Q110-Q311)
European IV Iron Market – by Volume (MAT2007-MAT2011)
IV Iron Usage in Switzerland by Value (2006-2010)
IV Iron Market Volume in Switzerland – by Products Categories (2002-2010)
IV Iron Usage in Switzerland – Value Share by Therapeutic Area (2010)
IV Iron Usage Growth by Therapeutic Area in Switzerland (2007-2010)
Stages of Chronic Kidney Disease (CKD)
Dialysis Patients Worldwide (2005-2010)
World Population with Diabetes, Age Group 20-79 years (2006-2012)
Ageing Population Worldwide, age>60 year (2008-2014E)
Global Female Population: age 15-44 years (2008-2014E)
IV Iron – Avoidance of ESA Initiation in Pre Dialysis Patients
IV Iron – Response Rate to ESA Therapy with or without IV Iron
IV Iron Cost Structure – by Products
Long & Short Term Concerns about IV Iron
Galenica Pharmaceuticals Revenue – Share by Segments (2010)
Vifor Pharma IV Iron Replacement Products – Revenue (2009-2010)
Watson Pharmaceuticals Revenue (2007-2010)
Watson Pharmaceuticals Revenue – Share by Segments (2010)
AMAG Pharmaceuticals – Revenue (2007-2010)
Feraheme Revenue (2009-2010)
Global IV Iron Market Forecasts (2010-2015E)

List of Tables

Comparison of Major IV Iron Preparations
Timeline of IV Iron Development in the US (1932-Present)
IV Iron Products – Administration Statistics
IV Iron Products – Safety Profile
Dependent & Independent Variables (2006-2010)
Correlation Matrix
Model Summary – Coefficient of Determination
Regression Coefficients Output

[Inhaltsverzeichnis ausblenden]